NCT02142803 2025-11-13TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid TumorsNational Cancer Institute (NCI)Phase 1 Active not recruiting50 enrolled 16 charts
NCT05179824 2025-05-06Tempus Priority Study: A Pan-tumor Observational StudyTempus AIActive not recruiting1,000 enrolled
NCT04913337 2024-10-02Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor MalignanciesNGM Biopharmaceuticals, IncPhase 1/2 Active not recruiting179 enrolled